Jacobs Levy Equity Management
SLNO

Jacobs Levy Equity Management’s Soleno Therapeutics SLNO Stock Holding History

Jacobs Levy Equity Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,813
Closed -$34K – 1108
2021
Q1 		$34K Sell
1,813
-3,060
-63% -$98.6K ﹤0.01% 1000
2020
Q4 		$141K Buy
+4,873
New +$141K ﹤0.01% 978

Other funds holding SLNO

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Jacobs Levy Equity Management's SLNO Position: Q2 2021 in Review

Jacobs Levy Equity Management sold out of Soleno Therapeutics (SLNO) in Q2 2021, closing a stake of 1,813 shares — an estimated $34K sold.

Jacobs Levy Equity Management first reported a position in SLNO in Q4 2020 and held it in 2 quarters. The position peaked at $141K in Q4 2020. 47 funds tracked by Wall St. Rank hold SLNO as of Q2 2021.

  • Jacobs Levy Equity Management reported no remaining Soleno Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 1,813 Soleno Therapeutics shares in Q2 2021, an estimated $34K.
  • Jacobs Levy Equity Management first reported a position in Soleno Therapeutics in Q4 2020 and held it in 2 quarters.
  • Jacobs Levy Equity Management's Soleno Therapeutics position peaked at $141K in Q4 2020.
  • 47 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2021, filed 16 Aug 2021.